DLD-1

DLD-1 (Colorectal Cancer CDX Model) 

The DLD-1 colorectal cancer cell line was derived from a patient with adenocarcinoma of the colon. It carries a KRAS mutation, representing a common driver in colorectal cancer. DLD-1 is widely used in colon cancer drug discovery and resistance studies. Its reproducibility has made it a staple in preclinical pipelines. 

Key Features: 

• Derived from colorectal adenocarcinoma. 

• KRAS-mutant colorectal cancer model. 

• Maintains epithelial morphology. 

• Consistent xenograft tumor growth. 

Applications: 
DLD-1 is applied in studies of KRAS-driven colorectal cancer biology. It supports drug discovery and biomarker validation for targeted therapies. Researchers use it to explore resistance to standard chemotherapies. Its defined mutation status provides strong translational relevance.